Eprodisate for the Treatment of Renal Disease in AA Amyloidosis
Author(s) -
Laura M. Dember,
Philip N. Hawkins,
Bouke P. C. Hazenberg,
Peter D. Gorevic,
Giampaolo Merlini,
İrena Butrimienė,
Avi Livneh,
O. M. Lesnyak,
Xavier Puéchal,
Helen J. Lachmann,
Laura Obici,
Robert Balshaw,
Denis Garceau,
W. Hauck,
Martha Skinner
Publication year - 2007
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa065644
Subject(s) - amyloidosis , amyloid (mycology) , fibril , aa amyloidosis , medicine , amyloid fibril , glycosaminoglycan , serum amyloid a , serum amyloid a protein , pathology , biochemistry , disease , chemistry , immunology , amyloid β , inflammation , anatomy , familial mediterranean fever
Amyloid A (AA) amyloidosis is a complication of chronic inflammatory conditions that develops when proteolytic fragments of serum amyloid A protein (SAA) are deposited in tissues as amyloid fibrils. Amyloid deposition in the kidney causes progressive deterioration in renal function. Eprodisate is a member of a new class of compounds designed to interfere with interactions between amyloidogenic proteins and glycosaminoglycans and thereby inhibit polymerization of amyloid fibrils and deposition of the fibrils in tissues.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom